89bio Reports Positive Topline Data From Extended Phase 2b ENLIVEN Trial Of Pegozafermin

Biopharmaceutical company 89bio, Inc. (ETNB) announced Monday positive topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis (NASH).

Related Keywords

United States , ,Drug Administration ,Walmart ,Acorn Baking Co ,Black Friday ,Country Gift Baskets ,Acorn Baking ,Cyber Monday ,